Published Date : Jun 20, 2016
A small-scale clinical trial conducted on 10 patients diagnosed with the early onset of Alzheimer’s disease has found that cognitive impairment and memory loss is reversible. These improvements were not only sustained, but a few of the patients even regained their ability to speak various languages, went back to work, and after just a few months, showed a rise in brain matter volume.
‘Patients Going from Abnormal to Normal’
Dale Bredesen, from the University of California, LA, states that all of the patients in the clinical trial had been either diagnosed with Alzheimer’s, present subjective cognitive impairment, or well-defined mild cognitive impairment before the start of the program. Follow-up tests revealed that some of the patients returning from abnormal to normal.
Effects of New Personalized Treatment under Review
The clinical trial is being conducted to evaluate the effects of a recent personalized treatment method on 10 patients’ cognitive abilities. These patients have been experiencing cognitive decline owing to age-associated diseases. The new treatment is called MEND, standing for metabolic enhancement for neurodegeneration. It is based on 36 distinct factors, such as exercise, integration of certain drugs, brain stimulation therapy, changes in diet, sleeping habits, and the addition of vitamins to their usual routine. These treatments and lifestyle changes were followed for a duration of five to 24 months and a team from the Buck Institute for Research on Ageing in California and UCLA has shown that several of the patients from the clinical trial were showing real and life-changing improvements as a result of the treatment.
Unprecedented Magnitude of Improvement
The researchers have stated that this is the first study of its kind to objectively prove that memory loss in patients of Alzheimer’s can truly be reversed and this improvement can be sustained. Bredesen claims that the scale of improvement that these 10 patients have shown is indeed unprecedented and offer additional and unbiased proof that this testing program to treat cognitive decline is immensely effective.